\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section.1.1}{Cancer Research in the Post-Genomic Era}{chapter.1}% 2
\BOOKMARK [2][-]{subsection.1.1.1}{The Human Genome Revolution}{section.1.1}% 3
\BOOKMARK [3][-]{section*.4}{The First Human Genome Sequence}{subsection.1.1.1}% 4
\BOOKMARK [3][-]{section*.5}{Expectations of Genomics}{subsection.1.1.1}% 5
\BOOKMARK [2][-]{subsection.1.1.2}{Technologies to Enable Genetics Research}{section.1.1}% 6
\BOOKMARK [3][-]{section*.6}{DNA Sequencing and Genotyping Technologies}{subsection.1.1.2}% 7
\BOOKMARK [3][-]{section*.7}{Microarrays and Quantitative Technologies}{subsection.1.1.2}% 8
\BOOKMARK [3][-]{section*.8}{Massively Parallel ``Next Generation'' Sequencing Technologies}{subsection.1.1.2}% 9
\BOOKMARK [4][-]{section*.9}{Established Sequencing Technologies}{section*.8}% 10
\BOOKMARK [4][-]{section*.10}{Emerging Sequencing Technologies}{section*.8}% 11
\BOOKMARK [3][-]{section*.11}{Bioinformatics as an Interdisciplinary Approach to Genomics Data}{subsection.1.1.2}% 12
\BOOKMARK [2][-]{subsection.1.1.3}{Follow-up Large-Scale Genomics Projects}{section.1.1}% 13
\BOOKMARK [2][-]{subsection.1.1.4}{Cancer Genomes}{section.1.1}% 14
\BOOKMARK [3][-]{section*.12}{The Cancer Genome Atlas Project}{subsection.1.1.4}% 15
\BOOKMARK [3][-]{section*.13}{The International Cancer Genome Consortium}{subsection.1.1.4}% 16
\BOOKMARK [3][-]{section*.14}{Subpopulation and Cell Line projects}{subsection.1.1.4}% 17
\BOOKMARK [2][-]{subsection.1.1.5}{Genomic Cancer Medicine}{section.1.1}% 18
\BOOKMARK [3][-]{section*.15}{Cancer Genes and Driver Mutations}{subsection.1.1.5}% 19
\BOOKMARK [3][-]{section*.16}{Personalised or Precision Cancer Medicine}{subsection.1.1.5}% 20
\BOOKMARK [4][-]{section*.17}{Molecular Diagnostics and Pan-Cancer Medicine}{section*.16}% 21
\BOOKMARK [3][-]{section*.18}{Targeted Therapeutics and Pharmacogenomics}{subsection.1.1.5}% 22
\BOOKMARK [4][-]{section*.19}{Targeting Oncogenic Driver Mutations}{section*.18}% 23
\BOOKMARK [4][-]{section*.20}{ Network Medicine, and Polypharmacology}{section*.18}% 24
\BOOKMARK [1][-]{section.1.2}{A Synthetic Lethal Approach to Cancer Medicine}{chapter.1}% 25
\BOOKMARK [2][-]{subsection.1.2.1}{Synthetic Lethal Genetic Interactions}{section.1.2}% 26
\BOOKMARK [3][-]{section*.21}{Synthetic Lethal Drug Design}{subsection.1.2.1}% 27
\BOOKMARK [2][-]{subsection.1.2.2}{Synthetic Lethal Concepts in Genetics}{section.1.2}% 28
\BOOKMARK [3][-]{section*.22}{Functional Genetics}{subsection.1.2.2}% 29
\BOOKMARK [4][-]{section*.23}{Conditional and Induced Essentiality}{section*.22}% 30
\BOOKMARK [4][-]{section*.24}{Functional Redundancy}{section*.22}% 31
\BOOKMARK [3][-]{section*.25}{Evolutionary and Developmental Biology}{subsection.1.2.2}% 32
\BOOKMARK [4][-]{section*.26}{Genetic Robustness and Network ``Re-wiring''}{section*.25}% 33
\BOOKMARK [3][-]{section*.27}{Cancer and Translational Biology}{subsection.1.2.2}% 34
\BOOKMARK [4][-]{section*.28}{Non-Oncogene Addiction}{section*.27}% 35
\BOOKMARK [2][-]{subsection.1.2.3}{Synthetic Lethal Concepts in Genetics}{section.1.2}% 36
\BOOKMARK [3][-]{section*.29}{Synthetic Lethal Pathways}{subsection.1.2.3}% 37
\BOOKMARK [3][-]{section*.30}{Experimental Inference}{subsection.1.2.3}% 38
\BOOKMARK [3][-]{section*.31}{Models and Computational Detection}{subsection.1.2.3}% 39
\BOOKMARK [2][-]{subsection.1.2.4}{The Potential of Synthetic Lethality for Anti-Cancer Medicine}{section.1.2}% 40
\BOOKMARK [3][-]{section*.32}{Rationale of Exploiting Synthetic Lethality in Cancers}{subsection.1.2.4}% 41
\BOOKMARK [4][-]{section*.33}{Indirect Targeting and Tumour Suppressor Genes}{section*.32}% 42
\BOOKMARK [4][-]{section*.34}{Synthetic Interactions and Gene Dosage}{section*.32}% 43
\BOOKMARK [4][-]{section*.35}{Homology and Indirect Targeting for Anti-Cancer Specificity}{section*.32}% 44
\BOOKMARK [2][-]{subsection.1.2.5}{Prior Studies on Synthetic Lethality}{section.1.2}% 45
\BOOKMARK [3][-]{section*.36}{Experimental Studies of Synthetic Lethality}{subsection.1.2.5}% 46
\BOOKMARK [4][-]{section*.37}{RNA interference in Eukaryotes}{section*.36}% 47
\BOOKMARK [3][-]{section*.38}{Examples of Clinical Impact}{subsection.1.2.5}% 48
\BOOKMARK [3][-]{section*.39}{High-throughput Screening for Synthetic Lethality}{subsection.1.2.5}% 49
\BOOKMARK [4][-]{section*.40}{Examples of High-throughput Synthetic Lethal Screens}{section*.39}% 50
\BOOKMARK [3][-]{section*.41}{Computational Prediction of Synthetic Lethality}{subsection.1.2.5}% 51
\BOOKMARK [1][-]{section.1.3}{E-cadherin as a Synthetic Lethal Target}{chapter.1}% 52
\BOOKMARK [2][-]{subsection.1.3.1}{The CDH1 gene and it's Biological Functions}{section.1.3}% 53
\BOOKMARK [3][-]{section*.42}{Cytoskeleton}{subsection.1.3.1}% 54
\BOOKMARK [3][-]{section*.43}{Extracellular and Tumour Micro-Environment}{subsection.1.3.1}% 55
\BOOKMARK [3][-]{section*.44}{Cell-Cell Adhesion and Signalling}{subsection.1.3.1}% 56
\BOOKMARK [2][-]{subsection.1.3.2}{CDH1 as a Tumour \(and Invasion\) Suppressor}{section.1.3}% 57
\BOOKMARK [3][-]{section*.45}{Breast Cancers and Invasion}{subsection.1.3.2}% 58
\BOOKMARK [2][-]{subsection.1.3.3}{Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer}{section.1.3}% 59
\BOOKMARK [2][-]{subsection.1.3.4}{Somatic Mutations}{section.1.3}% 60
\BOOKMARK [3][-]{section*.46}{Mutation Rate}{subsection.1.3.4}% 61
\BOOKMARK [3][-]{section*.47}{Co-occuring Mutations}{subsection.1.3.4}% 62
\BOOKMARK [2][-]{subsection.1.3.5}{Models of CDH1 loss in cell lines}{section.1.3}% 63
\BOOKMARK [1][-]{section.1.4}{Summary and Research Direction of Thesis}{chapter.1}% 64
\BOOKMARK [0][-]{chapter.2}{Methods, Techniques, and Resources}{}% 65
\BOOKMARK [1][-]{section.2.1}{Overview/meta-text}{chapter.2}% 66
\BOOKMARK [1][-]{section.2.2}{Bioinformatics to Enable Genomics Research}{chapter.2}% 67
\BOOKMARK [2][-]{subsection.2.2.1}{Public Data and Software Packages}{section.2.2}% 68
\BOOKMARK [3][-]{section*.48}{[more detail e.g., TCGA, Reactome]}{subsection.2.2.1}% 69
\BOOKMARK [2][-]{subsection.2.2.2}{Computational Tools and Enabling Biological Research \(remove/state assumptions only\)}{section.2.2}% 70
\BOOKMARK [3][-]{section*.49}{High Performance and Parallel Computing}{subsection.2.2.2}% 71
\BOOKMARK [2][-]{subsection.2.2.3}{Gene Expression Analysis and Statistical Challenges}{section.2.2}% 72
\BOOKMARK [3][-]{section*.50}{Hypothesis Testing and Multiple Comparisons Procedures}{subsection.2.2.3}% 73
\BOOKMARK [3][-]{section*.51}{Candidate Triage and Integration with Experimental Data}{subsection.2.2.3}% 74
\BOOKMARK [2][-]{subsection.2.2.4}{Mathematical Challenges in Bioinformatics}{section.2.2}% 75
\BOOKMARK [3][-]{section*.52}{Graph Theory, Systems, and Network Biology}{subsection.2.2.4}% 76
\BOOKMARK [3][-]{section*.53}{Matrix Operations and Pathway “Metagenes”}{subsection.2.2.4}% 77
\BOOKMARK [1][-]{section.2.3}{Data Handling}{chapter.2}% 78
\BOOKMARK [2][-]{subsection.2.3.1}{Normalisation \(voom\)}{section.2.3}% 79
\BOOKMARK [2][-]{subsection.2.3.2}{Sample triage}{section.2.3}% 80
\BOOKMARK [2][-]{subsection.2.3.3}{SVD/mg}{section.2.3}% 81
\BOOKMARK [1][-]{section.2.4}{Techniques}{chapter.2}% 82
\BOOKMARK [2][-]{subsection.2.4.1}{Clustering}{section.2.4}% 83
\BOOKMARK [2][-]{subsection.2.4.2}{Heatmap}{section.2.4}% 84
\BOOKMARK [2][-]{subsection.2.4.3}{Modeling and Simulations}{section.2.4}% 85
\BOOKMARK [3][-]{section*.54}{\(AU\)ROC}{subsection.2.4.3}% 86
\BOOKMARK [2][-]{subsection.2.4.4}{Permutation / Resampling}{section.2.4}% 87
\BOOKMARK [2][-]{subsection.2.4.5}{Network Metrics / Techniques}{section.2.4}% 88
\BOOKMARK [1][-]{section.2.5}{Pathway Structure Methods}{chapter.2}% 89
\BOOKMARK [2][-]{subsection.2.5.1}{Sourcing graph structure data}{section.2.5}% 90
\BOOKMARK [2][-]{subsection.2.5.2}{Constructing pathway subgraphs}{section.2.5}% 91
\BOOKMARK [2][-]{subsection.2.5.3}{Centrality Measures}{section.2.5}% 92
\BOOKMARK [2][-]{subsection.2.5.4}{Data Sources}{section.2.5}% 93
\BOOKMARK [0][-]{chapter.3}{Methods Developed During Thesis}{}% 94
\BOOKMARK [1][-]{section.3.1}{Overview/meta-text}{chapter.3}% 95
\BOOKMARK [1][-]{section.3.2}{Developing a Synthetic Lethal Detection Methodology}{chapter.3}% 96
\BOOKMARK [2][-]{subsection.3.2.1}{Rationale and Design of Test}{section.3.2}% 97
\BOOKMARK [2][-]{subsection.3.2.2}{Synthetic Lethal Detection Method}{section.3.2}% 98
\BOOKMARK [1][-]{section.3.3}{Simulations and Modelling Synthetic Lethality in Expression Data}{chapter.3}% 99
\BOOKMARK [2][-]{subsection.3.3.1}{Synthetic Lethal Modeling}{section.3.3}% 100
\BOOKMARK [2][-]{subsection.3.3.2}{Simulation Procedure}{section.3.3}% 101
\BOOKMARK [1][-]{section.3.4}{Assessing the Synthetic Lethal detection methodology \(simulation results part 1\)}{chapter.3}% 102
\BOOKMARK [2][-]{subsection.3.4.1}{Binomial Simulation of Synthetic lethality[?]}{section.3.4}% 103
\BOOKMARK [2][-]{subsection.3.4.2}{Multivariate Normal Simulation of Synthetic lethality[+dir?]}{section.3.4}% 104
\BOOKMARK [3][-]{section*.55}{Receiver Operating Characteristic Curves}{subsection.3.4.2}% 105
\BOOKMARK [3][-]{section*.56}{Simulated Expression Heatmaps}{subsection.3.4.2}% 106
\BOOKMARK [2][-]{subsection.3.4.3}{Replication Simulation Heatmap}{section.3.4}% 107
\BOOKMARK [1][-]{section.3.5}{Graph Structure Methods}{chapter.3}% 108
\BOOKMARK [2][-]{subsection.3.5.1}{Upstream and downstream gene detection}{section.3.5}% 109
\BOOKMARK [2][-]{subsection.3.5.2}{Permutation analysis}{section.3.5}% 110
\BOOKMARK [2][-]{subsection.3.5.3}{Simulating gene expression from graph structure}{section.3.5}% 111
\BOOKMARK [1][-]{section.3.6}{Customised methods and R packages developed}{chapter.3}% 112
\BOOKMARK [2][-]{subsection.3.6.1}{slipt}{section.3.6}% 113
\BOOKMARK [2][-]{subsection.3.6.2}{plotting}{section.3.6}% 114
\BOOKMARK [2][-]{subsection.3.6.3}{simulation from graph structures}{section.3.6}% 115
\BOOKMARK [2][-]{subsection.3.6.4}{igraph methods}{section.3.6}% 116
\BOOKMARK [0][-]{chapter.4}{Synthetic Lethal Analysis of Gene Expression Data}{}% 117
\BOOKMARK [1][-]{section.4.1}{Abstract}{chapter.4}% 118
\BOOKMARK [1][-]{section.4.2}{Aims and Significance}{chapter.4}% 119
\BOOKMARK [1][-]{section.4.3}{Background}{chapter.4}% 120
\BOOKMARK [1][-]{section.4.4}{Background}{chapter.4}% 121
\BOOKMARK [1][-]{section.4.5}{Sourcing TCGA data}{chapter.4}% 122
\BOOKMARK [1][-]{section.4.6}{Quality checking}{chapter.4}% 123
\BOOKMARK [1][-]{section.4.7}{Global Synthetic Lethality}{chapter.4}% 124
\BOOKMARK [1][-]{section.4.8}{CDH1 Analysis with Subgroups}{chapter.4}% 125
\BOOKMARK [1][-]{section.4.9}{Cell Line Analysis}{chapter.4}% 126
\BOOKMARK [1][-]{section.4.10}{Mutation, Copy Number, and Methylation}{chapter.4}% 127
\BOOKMARK [1][-]{section.4.11}{ANOVA of Expression Predictors}{chapter.4}% 128
\BOOKMARK [1][-]{section.4.12}{Mutation Analysis, Pathway Expression, and Metagene Synthetic Lethality}{chapter.4}% 129
\BOOKMARK [1][-]{section.4.13}{Data clean up, gene SL, and pathway SL}{chapter.4}% 130
\BOOKMARK [1][-]{section.4.14}{Overview of Challenges}{chapter.4}% 131
\BOOKMARK [1][-]{section.4.15}{Comparison of gene SL predictions and siRNA screen candidates}{chapter.4}% 132
\BOOKMARK [1][-]{section.4.16}{Permutation or Re-Sampling of genes for pathway enrichment.}{chapter.4}% 133
\BOOKMARK [1][-]{section.4.17}{Comparison of candidate SL Pathways}{chapter.4}% 134
\BOOKMARK [1][-]{section.4.18}{Future Directions}{chapter.4}% 135
\BOOKMARK [1][-]{section.4.19}{Hub Genes}{chapter.4}% 136
\BOOKMARK [1][-]{section.4.20}{Metagene pathway expression}{chapter.4}% 137
\BOOKMARK [1][-]{section.4.21}{Metagene synthetic lethality}{chapter.4}% 138
\BOOKMARK [1][-]{section.4.22}{Replication in stomach cancer}{chapter.4}% 139
\BOOKMARK [1][-]{section.4.23}{Important Results}{chapter.4}% 140
\BOOKMARK [0][-]{chapter.5}{Pathway Structure of Synthetic Lethal Genes}{}% 141
\BOOKMARK [1][-]{section.5.1}{Abstract}{chapter.5}% 142
\BOOKMARK [1][-]{section.5.2}{Background}{chapter.5}% 143
\BOOKMARK [1][-]{section.5.3}{Reactome Network structure and Information Centrality as a measure of gene essentiality}{chapter.5}% 144
\BOOKMARK [1][-]{section.5.4}{Synthetic lethal genes in synthetic lethal pathways}{chapter.5}% 145
\BOOKMARK [1][-]{section.5.5}{Methods}{chapter.5}% 146
\BOOKMARK [2][-]{subsection.5.5.1}{Sourcing graph structure data}{section.5.5}% 147
\BOOKMARK [2][-]{subsection.5.5.2}{Constructing pathway subgraphs}{section.5.5}% 148
\BOOKMARK [2][-]{subsection.5.5.3}{Centrality Measures}{section.5.5}% 149
\BOOKMARK [2][-]{subsection.5.5.4}{upstream and downstream gene detection}{section.5.5}% 150
\BOOKMARK [2][-]{subsection.5.5.5}{permutation analysis}{section.5.5}% 151
\BOOKMARK [1][-]{section.5.6}{Centrality and connectivity of synthetic lethal genes}{chapter.5}% 152
\BOOKMARK [1][-]{section.5.7}{Upstream or downstream synthetic lethal candidates}{chapter.5}% 153
\BOOKMARK [1][-]{section.5.8}{Hierachical approach}{chapter.5}% 154
\BOOKMARK [1][-]{section.5.9}{Discussion}{chapter.5}% 155
\BOOKMARK [1][-]{section.5.10}{Conclusion}{chapter.5}% 156
\BOOKMARK [0][-]{chapter.6}{Simulation and Modeling of Synthetic Lethal Pathways}{}% 157
\BOOKMARK [1][-]{section.6.1}{Abstract}{chapter.6}% 158
\BOOKMARK [1][-]{section.6.2}{Background}{chapter.6}% 159
\BOOKMARK [1][-]{section.6.3}{Simulations and Modelling Synthetic Lethality in Expression Data}{chapter.6}% 160
\BOOKMARK [1][-]{section.6.4}{Developing a Synthetic Lethal detection methodology}{chapter.6}% 161
\BOOKMARK [2][-]{subsection.6.4.1}{Testing Multivariate Normal Simulation of Synthetic lethality}{section.6.4}% 162
\BOOKMARK [2][-]{subsection.6.4.2}{Receiver Operating Characteristic Curves}{section.6.4}% 163
\BOOKMARK [2][-]{subsection.6.4.3}{Simulated Expression Heatmaps}{section.6.4}% 164
\BOOKMARK [2][-]{subsection.6.4.4}{Replication Simulation Heatmap}{section.6.4}% 165
\BOOKMARK [1][-]{section.6.5}{Simulation of synthetic lethality in graph structures}{chapter.6}% 166
\BOOKMARK [2][-]{subsection.6.5.1}{Developing a multivariate normal expression from graph structures}{section.6.5}% 167
\BOOKMARK [2][-]{subsection.6.5.2}{Simulations over simple graph structures}{section.6.5}% 168
\BOOKMARK [3][-]{section*.57}{Performance}{subsection.6.5.2}% 169
\BOOKMARK [3][-]{section*.58}{Synthetic lethality across graph stuctures}{subsection.6.5.2}% 170
\BOOKMARK [3][-]{section*.59}{Performance with inhibition links}{subsection.6.5.2}% 171
\BOOKMARK [3][-]{section*.60}{Performance with 20,000 genes}{subsection.6.5.2}% 172
\BOOKMARK [2][-]{subsection.6.5.3}{Simulations over pathway-based graphs}{section.6.5}% 173
\BOOKMARK [2][-]{subsection.6.5.4}{Comparing methods}{section.6.5}% 174
\BOOKMARK [3][-]{section*.61}{SLIPT and Chi-Squared}{subsection.6.5.4}% 175
\BOOKMARK [4][-]{section*.62}{Correlated query genes}{section*.61}% 176
\BOOKMARK [3][-]{section*.63}{Correlation}{subsection.6.5.4}% 177
\BOOKMARK [3][-]{section*.64}{Linear models}{subsection.6.5.4}% 178
\BOOKMARK [2][-]{subsection.6.5.5}{Developing a linear model predictor of synthetic lethality}{section.6.5}% 179
\BOOKMARK [3][-]{section*.65}{Linear models}{subsection.6.5.5}% 180
\BOOKMARK [3][-]{section*.66}{Polynomial models}{subsection.6.5.5}% 181
\BOOKMARK [3][-]{section*.67}{Conditioning}{subsection.6.5.5}% 182
\BOOKMARK [3][-]{section*.68}{SLIPTv2}{subsection.6.5.5}% 183
\BOOKMARK [1][-]{section.6.6}{Significance}{chapter.6}% 184
\BOOKMARK [1][-]{section.6.7}{Future Directions}{chapter.6}% 185
\BOOKMARK [1][-]{section.6.8}{Conclusion}{chapter.6}% 186
\BOOKMARK [0][-]{chapter.7}{Discussion}{}% 187
\BOOKMARK [0][-]{chapter.8}{Conclusion}{}% 188
\BOOKMARK [0][-]{chapter.8}{References}{}% 189
